ADVA
24.3.2021 08:02:08 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Vodafone Romania is using its carrier-grade network operating system (NOS) in a key trial of disaggregated cell site gateway (DCSG) technology in a live nationwide network. Built with ADVA’s Ensemble Activator software running on Edgecore’s new family of DCSG devices, the open multi-vendor transport network succeeded in carrying 2G, 3G, 4G and 5G traffic while also interoperating with Vodafone’s existing infrastructure. The trial is a key step towards Vodafone validating the disaggregated model.
“We are pleased to contribute to the innovation in the field of open telecom networks, facilitating the validation of the open cell site gateway concept in a live network scenario while following our existing standard practices and processes. It was a smooth introduction, proving that the concept of open telecom networks where hardware is decoupled from software is feasible – not only in core network platforms through virtualization and in mobile radio access networks through the OpenRAN, but now also in the IP transport layer,” said Catalin Buliga, CTO, Vodafone Romania. “Mobile networks have been for years locked into a limited number of traditional telecom equipment vendors. By investing in developing open networks, where the hardware and software are decoupled, we open the gate to a wide range of suppliers for hardware, a wide range of suppliers for software, we accelerate innovation and increase our resilience.”
By using ADVA and Edgecore’s technology in a complete and fully tested DCSG offering, the trial gives Vodafone Romania insight into new mobile transport opportunities. Developed within the Telecom Infra Project’s Open Optical & Packet Transport group, the solution provides an open, agile and scalable solution able to meet today’s protocol requirements and is adaptable with future needs. Its hardware-supported SyncE and IEEE 1588 timing, with optional SFP-based GNSS backup, fulfills the most stringent synchronization accuracy requirements.
“This latest trial highlights how major mobile network operators have an alternative simple and cost-effective route to the deployment for 5G services. Our open and feature-rich Ensemble Activator NOS and Edgecore’s high-performance white boxes free network operators from closed proprietary systems. They enable them to deploy vendor-neutral disaggregated architectures using best-in-class components,” commented Eli Angel, VP, product line management, ADVA. “Today’s customers expect vendors to work side by side and build open solutions that can easily fit into complex heterogeneous environments. But while some in the industry do little more than talk about their commitment to collaboration and openness, we’re continually proving it. Now, trials like this are making the value of our approach abundantly clear.”
“As the leading provider of open network solutions to Tier 1 operators worldwide, and the leading contributor to the OCP, ONF, and TIP open communities, Edgecore understands the requirement to accelerate the innovation of disaggregated open network deployments while moving toward a more consistent and open infrastructure across mobile broadband and transport networks,” noted George Tchaparian, CEO and president, Edgecore Networks. “This successful live trial in Romania is yet another proof point that open networking is robust and deployable in the most demanding network environments.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005010/en/
Social Media:
https://www.facebook.com/pages/ADVA-Optical-Networking/37630238931
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
DCX builds coolant chemistry control into its 8 MW Facility Distribution Unit19.10.2026 14:01:00 CEST | Press release
DCX introduces groundbreaking new safety standard protecting critical AI infrastructure by monitoring and keeping the entire coolant loop Continuous monitoring of eight coolant parameters and automatic dosing keep hall-scale liquid-cooling loops in specification between service visits Today DCX Liquid Cooling Systems announced worldwide’s first CDU system with built-in coolant control and treatment system. DCX integrated this coolant quality feature into it’s Facility Coolant Distribution Units: a family of 5-8 MW capable hyperscale-class coolant Distribution Units. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014488003/en/ DCX announces the world’s first CDU with built-in coolant quality control and treatment - a new safety standard for hall-scale Liquid Cooling in critical AI infrastructure. The FDU monitors the chemistry of its coolant continuously and corrects it automatically with integrated electronic dosing pumps
STARTEEPO Sends Letter to Xerox Board in Advance of Third-Quarter Earnings19.10.2026 14:00:00 CEST | Press release
Company’s Third Largest Shareholder Expects Update on Increased Transparency, Strategic Review of Xerox Financial Services Business Unit, and Continued DeleveragingSTARTEEPO Chairman František Bostl to Address Xerox Investment at Skytop Conference in London STARTEEPO SICAV a.s. (“STARTEEPO”), which beneficially owns 7.34% of Xerox Holdings Corporation (“Xerox” or the “Company”) (NASDAQ: XRX) in stocks and options, today issued the following letter to the Xerox Board of Directors (the “Board”): October 19, 2026 The Board of Directors Xerox Holdings Corp. 401 Merritt 7 Norwalk, CT 06851 Dear Members of the Board: Our open letter to the Board in early September helped spark a lively conversation about the future of this iconic company among investors and throughout the print industry. Despite these efforts, Xerox’s share price still does not reflect the significant value we see in the Company, a gap recently confirmed by Citi’s downgrade of Xerox stock to reflect the challenge of executin
The Data Center Marketplace Is Booming, Inaugural Data Center World Europe Unites Data Center and Energy Decision-Makers and Expertsin Vienna19.10.2026 12:00:00 CEST | Press release
Data Center World Europe 2027 took place October 13-15 at VIECON – Vienna Congress & Convention Center in Austria Last week, Data Center World Europe, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators over three days at VIECON – Vienna Congress & Convention Center in Vienna, Austria. It was co-located with the leading global network infrastructure event Network X, where data centre developers, AI and cloud providers, energy and utility operators, and solution providers come together to drive the development of an AI-ready, sustainable future, united leading operators, technologists, cloud providers, hyperscalers and energy management innovators. Tara Gibb, Senior Director, Data Center World Europe said, “The conference tackled the industry’s most urgent
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 202619.10.2026 12:00:00 CEST | Press release
New data from four priority programs, including the GPC3x4-1BB bispecific antibody, CEA targeting ADC, CDK4 inhibitor, and brain-penetrant PRMT5 inhibitor underscore the depth of BeOne’s solid tumor pipelineMultiple TEVIMBRA abstracts reinforce breadth of evidence across lung and gastrointestinal cancers, including data in combination with ZIIHERA in HER2+ gastroesophageal cancer BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from across its rapidly progressing solid tumor portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress 2026 on October 23-27 in Madrid. Presentations will highlight an accelerating pipeline of differentiated targeted therapies, alongside a broad body of evidence for TEVIMBRA® (tislelizumab), including a late-breaking rapid oral presentation on TEVIMBRA in combination with ZIIHERA® (zanidatamab) in HER2+ gastroesophageal adenocarcinoma (GEA). Priority pipeline data
First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication19.10.2026 11:30:00 CEST | Press release
More than half of ENTYVIO patients who met their assigned treatment target reached disease clearance (composite of corticosteroid-free symptomatic, endoscopic and histologic remission) at Week 16VERDICT is the first trial to provide macroscopic and microscopic evidence of intestinal tissue repair associated with disease clearance in largely bio-naïve patients treated with an advanced therapy Takeda (TSE:4502/NYSE:TAK) announced new data from VERDICT (NCT04259138), showing that treating adults with intravenous ENTYVIO® (vedolizumab) to achieve corticosteroid-free (CSF) disease clearance versus CSF symptomatic remission alone, resulted in a significantly longer time to first ulcerative colitis (UC)-related complication (hazard ratio 0.33 [95% confidence interval 0.17-0.67]; P=0.0014), reducing UC complication risk by nearly 70 percent. VERDICT, a Phase 4 ENTYVIO clinical trial, provides the first prospective, randomized evidence that disease clearance is an achievable and clinically rel
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom